Fidelity Investments
GLUE icon

Fidelity Investments’s Monte Rosa Therapeutics GLUE Stock Holding History

Fidelity Investments’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Sell
934,414
-89,890
-9% -$1.7M ﹤0.01% 1840
2026
Q1 		$16.8M Sell
1,024,304
-275,792
-21% -$5.27M ﹤0.01% 1850
2025
Q4 		$20.4M Sell
1,300,096
-1,512,155
-54% -$20.4M ﹤0.01% 1765
2025
Q3 		$20.8M Buy
2,812,251
+524,217
+23% +$2.78M ﹤0.01% 1742
2025
Q2 		$10.3M Sell
2,288,034
-2,386,074
-51% -$10.6M ﹤0.01% 1918
2025
Q1 		$21.7M Sell
4,674,108
-874,340
-16% -$5.36M ﹤0.01% 1649
2024
Q4 		$38.5M Buy
5,548,448
+447,035
+9% +$3.35M ﹤0.01% 1487
2024
Q3 		$27M Buy
5,101,413
+6,439
+0.1% +$32.5K ﹤0.01% 1610
2024
Q2 		$19.1M Sell
5,094,974
-245,828
-5% -$1.25M ﹤0.01% 1670
2024
Q1 		$37.7M Sell
5,340,802
-196,437
-4% -$1.17M ﹤0.01% 1424
2023
Q4 		$31.3M Sell
5,537,239
-467,594
-8% -$1.83M ﹤0.01% 1468
2023
Q3 		$28.8M Sell
6,004,833
-540,899
-8% -$3.48M ﹤0.01% 1458
2023
Q2 		$44.8M Buy
6,545,732
+124,693
+2% +$806K ﹤0.01% 1318
2023
Q1 		$50M Buy
6,421,039
+203,581
+3% +$1.42M ﹤0.01% 1266
2022
Q4 		$47.3M Buy
6,217,458
+12,484
+0.2% +$104K ﹤0.01% 1274
2022
Q3 		$50.7M Sell
6,204,974
-7,570
-0.1% -$69.5K 0.01% 1242
2022
Q2 		$60.1M Sell
6,212,544
-782,004
-11% -$7.86M 0.01% 1182
2022
Q1 		$98.1M Buy
6,994,548
+18,661
+0.3% +$259K 0.01% 1071
2021
Q4 		$142M Buy
6,975,887
+18,603
+0.3% +$390K 0.01% 932
2021
Q3 		$153M Buy
6,957,284
+2,645,025
+61% +$75.8M 0.01% 927
2021
Q2 		$93.5M Buy
+4,312,259
New +$87.8M 0.01% 1144

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's GLUE Position: Q2 2026 in Review

Fidelity Investments reduced its Monte Rosa Therapeutics (GLUE) stake by 8.8% in Q2 2026, selling an estimated $1.7M and leaving 934,414 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1840.

Fidelity Investments first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. The position peaked at $153M in Q3 2021. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Fidelity Investments held 934,414 shares of Monte Rosa Therapeutics worth $22.6M as of Q2 2026.
  • Fidelity Investments sold 89,890 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.7M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1840 holding.
  • Fidelity Investments first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Fidelity Investments's Monte Rosa Therapeutics position peaked at $153M in Q3 2021.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.